Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3164530 · 1 trial · 2 indications
Recommended Phase 2 Dose of LY3164530: MTD
| Arm | Type | Description |
|---|---|---|
| LY3164530 | EXPERIMENTAL | LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met. |
| Name | Type | Description |
|---|---|---|
| LY3164530 | DRUG | Administered IV. |
Inclusion Criteria * Have advanced or metastatic cancer and be an appropriate candidate for experimental therapy. * Have adequate organ function. * Prior Treatments: * Systemic treatments: Must have discontinued previous systemic treatments for cancer and recovered from the acute effects of ther...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
LY3164530 is an investigational small molecule being studied for the treatment of neoplasms, including neoplasm metastasis. It is developed by Eli Lilly and Company and is intended for use in oncology. As of the available data, it has completed a Phase 1 clinical trial.
LY3164530 is developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The drug is an investigational oncology therapy that has been studied in a Phase 1 clinical trial for the treatment of neoplasms.
LY3164530 is in Phase 1 of clinical development. It has completed a Phase 1 trial, and there are no active trials currently listed. The drug remains investigational and has not been approved by regulatory authorities.
LY3164530 has been studied in one clinical trial with the identifier NCT02221882, titled 'A Study of LY3164530 in Participants With Cancer'. This Phase 1 trial was completed and enrolled 29 participants with neoplasms or neoplasm metastasis in the United States.
LY3164530 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug is still in clinical development and has not been authorized for marketing or use outside of clinical trials.